Evidence map›Paper›PMID 34754606›Full record

ArticleAmerican journal of nuclear medicine and molecular imaging2021

Single-center developing country analysis of radium-223 therapy in prostate cancer-preliminary results.

Thaís B Minekawa, Allan O Santos, André G Moraes, André Sasse, Cleide A Silva, Marcelo T Lima, Mariana Camacho, Mariana C Lima, Elba Etchebehere

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 76% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Thaís B MinekawaDivision of Nuclear Medicine of The Department of Radiology, University of Campinas (UNICAMP) Campinas, Brazil.
Allan O SantosDivision of Nuclear Medicine of The Department of Radiology, University of Campinas (UNICAMP) Campinas, Brazil.
André G MoraesCentro de Oncologia Campinas (COC) Campinas, Brazil.
André SasseGrupo SONHE Campinas, Brazil.
Cleide A SilvaDepartment of Statistics, University of Campinas (UNICAMP) Campinas, Brazil.
Marcelo T LimaDepartment of Statistics, University of Campinas (UNICAMP) Campinas, Brazil.
Mariana CamachoMedicina Nuclear de Campinas (grupoMND) Campinas, Brazil.
Mariana C LimaDivision of Nuclear Medicine of The Department of Radiology, University of Campinas (UNICAMP) Campinas, Brazil.
Elba EtchebehereDivision of Nuclear Medicine of The Department of Radiology, University of Campinas (UNICAMP) Campinas, Brazil.
Universidade Estadual de Campinas (UNICAMP) · BRPontifícia Universidade Católica de Campinas · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We reviewed the records of mCRPC patients treated with off-label use of Ra-223. Ra-223 efficiency in this non-study population was correlated to outcome measures overall survival (OS), progression-free survival (PFS), bone event-free survival, bone marrow failure (BMF), and disease-related biomarkers. There were no limits regarding the number of prior hormonal agents or chemotherapy received before or during Ra-223. Exclusion criteria consisted of baseline platelet counts below 50,000/mm

Indexed as

bone metastasisprostate cancerRadium-223

Identifiers

PMID34754606
PMCPMC8569335
OpenAlexW3212884971

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.